NCT07190300
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07190300
Title TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (TulmiSTAR-02)
Acronym TulmiSTAR-02
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.